BioPearl™ Microspheres Loaded with Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma — A Prospective, Single-Arm, Multicenter Post-Market Clinical Follow-up Study
Main Facility: Radiologia diagnostica ed Interventistica
Drug: Doxorubicin
Pathologies: Hepatocellular carcinoma (HCC)
ClinicalTrials.gov: Read more about clinical trials
BIOPEARL-ONE is a prospective, single-arm, multicenter post-market clinical follow-up study designed to evaluate the safety and effectiveness of BioPearl™ microspheres loaded with doxorubicin in patients with unresectable hepatocellular carcinoma (HCC).
The study focuses on transarterial chemoembolization (TACE), where drug-eluting microspheres deliver localized chemotherapy directly to liver tumors while simultaneously blocking tumor blood supply. Outcomes typically include tumor response, overall survival, progression-free survival, and treatment-related adverse events in a real-world clinical setting.
Last update: 20/04/2026